Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 14, 2026
TickeronGET DAILY SIGNALS
Q32 Bio (QTTB): Assessing the Path to the $40 Target and a +359% Move

Q32 Bio (QTTB): Assessing the Path to the $40 Target and a +359% Move

Key Takeaways

  • The central $40 target is the arithmetic mean of seven verified analyst price targets, rounded from an average of about $39.43.
  • Q32 Bio Inc. (QTTB) last traded near $8.72, so reaching $40 implies a gain of roughly 359% — a very large move.
  • The individual targets range from $29 to $59, reflecting unusually wide disagreement about a clinical-stage biotech's blockbuster potential.
  • The strongest support comes from a Strong Buy consensus and positive data for lead candidate bempikibart in alopecia areata.
  • The biggest risks are clinical-stage status, cash burn, binary trial outcomes, and competition from already-approved treatments.
  • For deeper context on this ticker, explore Major News, Today's Price Move, the Forecast, and Earnings pages.

Analyst Price Targets and Consensus View

Q32 Bio is a clinical-stage biotechnology company developing biologics designed to restore healthy immune balance, with lead candidate bempikibart aimed at severe and very severe alopecia areata. Because the company is pre-revenue in any meaningful commercial sense, its stock price target depends almost entirely on clinical progress and the estimated size of its addressable market rather than near-term earnings.

Seven current, attributable analyst price targets were reviewed: Leerink Partners at $40 (reiterated November 5, 2026), Oppenheimer at $40 (November 5, 2026), Morgan Stanley at $34 (November 5, 2026), Wells Fargo at $59 (November 5, 2026), H.C. Wainwright at $36 (November 4, 2026), Clear Street at $38, and Jefferies at $29. That produces a mean of roughly $39.43, rounded to a $40 central target, with a range of $29 to $59. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The wide spread reflects a common pattern in biotech coverage: bullish analysts model bempikibart as a potential blockbuster in an underserved severe alopecia areata population, while more cautious analysts discount for execution and regulatory risk. The consensus is uniformly constructive — no Hold or Sell ratings appear among the current targets — but the $30 gap between the low and high estimates signals genuine uncertainty about the size of the opportunity.

Current Market Position and Path Toward the Target

With the stock near $8.72, moving to $40 requires upside of about 359%, a very large move by any standard. The shares have already been extraordinarily volatile, trading within a 52-week range of roughly $1.90 to $23.57. Notably, the $40 target sits well above the 52-week high, meaning the market would need to assign meaningfully more value than it has at any point in the past year.

The path would most likely run through continued positive readouts from the bempikibart program, successful regulatory filings, and eventual commercialization. In its most recent quarterly report, the company posted a narrower-than-expected loss per share, and H.C. Wainwright raised its target after what it described as positive week 36 data — a key catalyst that helped lift the stock from the low single digits.

What Could Support a Move Toward the Target

  • Positive clinical data. Favorable bempikibart results, particularly in severe alopecia areata, have already driven sharp target increases; further positive readouts could extend that trend.
  • Analyst conviction. The Strong Buy consensus and several recent initiations and target raises reflect growing confidence in the program's commercial potential.
  • Underserved market. Analysts who see a blockbuster opportunity argue severe and very severe alopecia areata remains inadequately addressed despite existing therapies.
  • Beating expectations. A smaller-than-expected quarterly loss has helped sustain momentum and supports the thesis of disciplined cash management.

What Could Prevent the Target From Being Reached

  • Clinical-stage risk. With no approved products generating material revenue, a failed or disappointing trial could severely compress valuation.
  • Cash burn and dilution. Funding late-stage trials typically requires additional capital raises, which can dilute existing shareholders.
  • Competition. Approved JAK inhibitors from larger pharmaceutical companies already serve the alopecia areata market, pressuring any future entrant.
  • Valuation gap. The $40 target implies a market capitalization far above today's roughly $260 million, a bar the company must earn through clinical success rather than near-term financials.

Technical Levels and Market Structure

The stock's 52-week range of roughly $1.90 to $23.57 frames its recent behavior. After trading near the lows, the shares have recovered to the high single digits, but the prior high near $23.57 remains a meaningful technical hurdle well below the $40 target. A sustained move toward $40 would require clearing that prior high and establishing new territory, so investors may view the $23–$24 zone as an important resistance area and the single-digit range as a key support level on pullbacks. From what I see, reviewing patterns with available tools helps put these levels in perspective.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though individual assumptions vary. For Q32 Bio, the most important items to watch are bempikibart clinical data readouts, regulatory interactions with the FDA, quarterly cash position and burn rate, and any analyst target revisions that follow new data. Because the company is pre-revenue, trial milestones — not earnings beats — are likely to be the dominant driver of whether the shares can move toward the $40 level.

Final Assessment

The $40 central target for Q32 Bio — the mean of seven verified analyst targets ranging from $29 to $59 — represents an aspiration anchored in bempikibart's blockbuster potential rather than current fundamentals. Reaching it would require a roughly 359% advance and a market re-rating well beyond the stock's 52-week high, making it a very large move. The Strong Buy consensus and positive recent data support the bullish case, while clinical-stage risk, cash needs, and competition from approved therapies remain substantial obstacles. The wide analyst range underscores genuine uncertainty. Investors should monitor clinical readouts and cash position above all, with no guarantee the target will be reached.

AI Daily Buy/Sell Signals in Practice

I find Tickeron's AI Daily Buy/Sell Signals helpful for tracking how market conditions and technical factors evolve for names like this one. The system monitors thousands of stocks and ETFs to generate Buy, Sell, or Hold signals, which can complement fundamental work when reviewing entry points or watching for shifts in momentum. It has become a regular part of how I cross-check ideas without replacing core research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: QTTB

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Aroon Indicator for QTTB shows an upward move is likely

QTTB's Aroon Indicator triggered a bullish signal on November 17, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 188 similar instances where the Aroon Indicator showed a similar pattern. In 165 of the 188 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where QTTB's RSI Indicator exited the oversold zone, 24 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +5.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where QTTB advanced for three days, in 209 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

QTTB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QTTB as a result. In 81 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

The 50-day moving average for QTTB moved below the 200-day moving average on November 11, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where QTTB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. QTTB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.600) is normal, around the industry mean (3.592). P/E Ratio (2.946) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (3.034) is also within normal values, averaging (442.120).

The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QTTB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
830 Winter Street
Phone
+1 718 999-0232
Employees
24
Web
https://www.q32bio.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.
Q32 Bio (QTTB): Assessing the Path to the $40 Target and a +359% Move